Actinium Pharmaceuticals, Inc.
New York, NY · CIK 0001388320 · Biotech · Public
Radiolabeled anti-CD45 antibody (131-I apamistamab) for conditioning prior to CAR T-cell therapy
actiniumpharma.com →- Grants
- $2.1M
- 3 awards
- Sector median: 1
- Raised
- $3.3M
- 5 Form D · Jan 2014
- 153 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 17 granted · 23 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20132015201720192021202320252027
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $3,325,860 | |
| Federal grant | Department of Health and Human Services · Phase II · Iomab-ACT: A phase I/II study of 131-I apamistamab targeted lymphodepletion followed by CD19-targeted CAR T-cell therapy for patients with relapsed or refractory B-ALL or DLBCL | $378,389 | |
| Federal grant | Department of Health and Human Services · Phase II · Iomab-ACT: A phase I/II study of 131-I apamistamab targeted lymphodepletion followed by CD19-targeted CAR T-cell therapy for patients with relapsed or refractory B-ALL or DLBCL | $865,308 | |
| Federal grant | Department of Health and Human Services · Phase II · Iomab-ACT: A phase I/II study of 131-I apamistamab targeted lymphodepletion followed by CD19-targeted CAR T-cell therapy for patients with relapsed or refractory B-ALL or DLBCL | $865,308 |
Federal grant · SBIR/STTRForm D · SECPress
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3314 | Hope Portal Services, Inc. | — | $250K |
| 3315 | Hemostemix Inc. | — | $132K |
| 3316 | Zag Bio | — | — |
| 3317 | Actinium Pharmaceuticals, Inc. | — | $3.3M |
| 3318 | ImmunoGen | — | — |
| 3319 | Cypre, Inc. | — | $3.2M |
| 3320 | Optimeos Life Sciences, Inc. | — | $3.3M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Press
Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing UpdatePRNewswire
Founders & Team
- Dragan CicicExecutive Officer
- Kaushik DaveDirector · Executive Officer
- David NicholsonDirector
- Sandesh SethDirector
- Richard SteinhartDirector
- Jack TalleyDirector · Executive Officer
- Sergio TraversaDirector · Executive Officer
Patents
- Compositions And Methods Of Immunodepletion For The Treatment Of Malignant And Non-malignant Hematological Diseasesgranted
- HER3 Radioimmunotherapy For The Treatment Of Solid Cancersgranted
- DR5 Radioimmunotherapy In The Treatment Of Solid Cancersgranted
- Stabilized Radiolabeled ANTI-CD45 Immunoglobulin Compositionsgranted
- Low dose antibody-based methods for treating hematologic malignanciesapplication
- Antibodies Conjugated With Actinium-225 and Actinium-227, and Related Compositions and Methodsapplication
- Calreticulin Nanobodiesgranted
- Molecules And Their Derivatives Directed Aganist CD45application
- Radiolabeling Of ANTI-CD45 Immunoglobulin And Methods Of Use Thereofgranted
- Radioconjugates Targeting CD33 In The Treatment Of Breast Cancerapplication
- Lewis Y Radioimmunotherapy For The Treatment Of Cancergranted
- Radioconjugates Targeting CD33 In The Treatment Of Cancersgranted
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.